The company has named several academic partners for the study, and expects pilot data this year and further analyses by the end of 2017.
The study found that ctDNA and tissue testing can fail to match up in many cases, but supports independent and complementary value for the two methods.
COTA, which also received funding from HealthScape Advisors, said it aims to reduce the amount of money wasted on unnecessary medical treatment.
In a complaint filed yesterday, Foundation claims that the Guardant360 test infringes its US Patent No. 9,340,830.
The diagnostic test is intended to help physicians decide if and how to use Mirati's targeted therapy in non-small cell lung cancer patients.
Principia will use Guardant's liquid biopsy assay to monitor the response of patients in a clinical trial of its FGFR inhibitor.
The partners will study testing rates, repeat biopsies and their complications, and other factors that preclude routine genotyping in NSCLC.
According to Gizmodo, researchers have developed a list of a million nucleic acid-like polymers that could store genetic information.
An opinion piece in the Washington Post argues that golden rice could save the sight and lives of many children.
US National Institutes of Health has issued a new draft data-sharing policy, ScienceInsider reports.
In Cell this week: analysis of immune microenvironment in hepatocellular carcinoma, proteogenomic analysis of clear cell renal cell carcinoma, and more.